Company profile
GeoVax Labs, Inc.
NASDAQ: GOVX · Healthcare · Biotechnology
#776 of 1,422 Healthcare companies by revenuebottom-quartile growth
EA Score
38DFH 24DQ 46GM 62SS 36
v0.1 · 65/100 weight · provisional
↑ 3-yr revenue growth, growth stability · ↓ return on equity, return on assets
Methodology →Revenue TTM
$852.3k
Rev growth YoY (TTM)
-84.8%
Net income (FY)
-$21.5M
Employees
19
as of 2026-08-26
Market cap
$4.7M
as of 2026-08-26
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$2.5M$2.5M2025
Net income-$21.5M-$21.5M2025
Operating income-$21.6M-$21.6M2025
Total assets$6.3M$6.3M2025
Liabilities$2.5M$2.5M2025
Equity$3.8M$3.8M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2022
By product
NIH Grants100%
By geography
Not disclosed.
The read
What is GeoVax Labs, Inc.’s revenue?
GeoVax Labs, Inc. booked $2.5M in FY2025 revenue, contracting 37% year over year — slower than 78% of Healthcare companies we track, at a -862.3% net margin.
Peers · Healthcare
Infinity Pharmaceuticals, Inc.——ENvue Medical, Inc.46DFiore Cannabis Ltd.——Wayland Group Corp.——Lattice Biologics Ltd.——Quantum-Si incorporated40DNeighbors
Cobb →Key facts
CEODavid Alan Dodd
SectorHealthcare
IndustryBiotechnology
HeadquartersSmyrna, GA
ExchangeNASDAQ: GOVX
Employees19
IPO date2020-09-25
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.